Epidermal growth factor receptor (EGFR), Tumor protein p53 (TP53), Catenin beta 1 (CTNNB1), Cyclin D1 (CCND1), and HRas proto-oncogene GTPase (HRAS) (EGFR, TP53, CTNNB1, CCND1, HRAS)

The input 'EGFR, TP53, CTNNB1, CCND1, HRAS' represents a collection of five distinct proteins rather than a single therapeutic target. Epidermal Growth Factor Receptor (EGFR) is a transmembrane receptor tyrosine kinase that activates signaling pathways like MAPK and PI3K/Akt to drive cell growth and survival (UniProt P00533). Tumor Protein p53 (TP53) is a critical transcription factor and tumor suppressor that orchestrates DNA repair, cell cycle arrest, and apoptosis in response to cellular stress (UniProt P04637). Catenin Beta 1 (CTNNB1) serves a dual role in maintaining cell-cell adhesion and acting as a downstream effector of the Wnt signaling pathway to regulate gene expression (UniProt P35222). Cyclin D1 (CCND1) is a key regulator of the G1 to S phase transition in the cell cycle, often overexpressed in various cancers (UniProt P24385). HRas Proto-Oncogene (HRAS) is a small GTPase that acts as a molecular switch in signal transduction pathways (UniProt P01112). While each of these proteins is a significant therapeutic target or biomarker individually, they do not form a single functional complex or a unified drug target (NIH, StatPearls).

Other names

ErbB-1HER1p53Beta-cateninBCL1PRAD1p21rasCTNNBCCND1-CDK4 complex

The mechanisms of action for drugs targeting these proteins are diverse: EGFR inhibitors block tyrosine kinase activity or ligand binding to prevent downstream signaling; CDK4/6 inhibitors prevent CCND1-mediated cell cycle progression from G1 to S phase; farnesyltransferase inhibitors prevent HRAS membrane localization; and TP53-targeting agents aim to restore the functional conformation of mutant p53 proteins (NIH, StatPearls, PubMed).